Sleuth

daily dose of biotech & healthcare commentary • founder @sleuthinsights • building software for the bioeconomy

Sleuth is a biopharma intelligence platform aimed at the teams making the field's most expensive calls: business development leads sizing up acquisitions, strategy groups committing to pipeline bets, and investors deciding where to put capital. The product lets a user point at a therapeutic area and, within minutes, assemble a structured view of every relevant program, mechanism, and competitor, then drill into head-to-head clinical benchmarks, deal comps, and indication fit. Sleuth is built on a proprietary knowledge graph that continuously acquires, structures, and links information from across the biopharma ecosystem , which is how it claims to surface assets and connections that single-source databases miss. The company was founded in 2023 by Andrew Pannu , a biopharma analyst who had been writing publicly about deal strategy and M&A patterns before starting the company, and it is based in Los Angeles. Sleuth has raised roughly $8 million and says its platform is already in use at large pharma BD, strategy, and investing teams, with outputs that include memos, slides, and benchmarks in a customer's own format rather than static dashboards. The pitch is a compression of work that would otherwise sit with outside consultants for weeks, with analyses that keep updating as new trials, deals, and readouts land. The launch is paired with a public teardown of the Chinese biopharma landscape, covering more than 18,000 assets and a view of where the strategic white space sits heading into 2026, which is both a marketing hook and a demonstration of what the platform can produce on a real question. For founders and operators watching how AI tools are moving into regulated, data-heavy verticals, Sleuth is a concrete test case in life sciences, where the bottleneck has long been messy, fragmented source data rather than raw model capability.

Tags

Comments (7)